Results 141 to 150 of about 14,491 (226)

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study. [PDF]

J Am Heart Assoc
Lin CY, Su PL, Kuo CW, Tsai IL, Liu TH, Yang J, Lin CC, Lin SH.   +7 more
europepmc   +1 more source

Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with <i>ALK</i>-positive non-small cell lung cancer. [PDF]

Future Sci OA
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Lohmann TO, Xu T, Cardona A, Hiles L, Noe J, Solomon BJ.   +21 more
europepmc   +1 more source

Alectinib as salvage therapy for metastatic UIMT following misdiagnosis: A case enabling definitive surgery and prolonged remission. [PDF]

Gynecol Oncol Rep
Shuang T, Wang XL, Wang Y, Jun BL.
europepmc   +1 more source

High-Speed Atomic Force Microscopy Reveals Disordered Region-Mediated Structural Plasticity of Anaplastic Lymphoma Kinase Fusion Proteins Induced by Inhibitors. [PDF]

ACS Nano
Han X, Kodera N, Yilmaz N, Sakai K, Arai S, Li B, Imamura R, Voon DC, Fukuda K, Nanjo S, Flechsig H, Mano H, Matsumoto K, Yano S.   +13 more
europepmc   +1 more source

Hepatotoxicity of new-generation ALK inhibitors versus crizotinib in patients with non-small cell lung cancer: A systematic review and meta-analysis. [PDF]

iScience
Luo X, Du X, Chen Q, Wang C, Li L, He X, Gong Y, Chen J, Zhong X, Liu Y, Zhang X, Huang L.   +11 more
europepmc   +1 more source

Cost-utility and budget impact analyses of anaplastic lymphoma kinase inhibitors in Thailand. [PDF]

Sci Rep
Luksameesate P, Phatchararuangkit N, Soopairin S, Vinayanuwattikun C, Kulthanachairojana N, Taychakhoonavudh S.   +5 more
europepmc   +1 more source

Adverse events associated with sequential immune checkpoint inhibitor and alectinib in patients with ALK-rearranged advanced non-small-cell lung cancer. [PDF]

ESMO Open
Cheung JM, Waliany S, Yeap BY, Peterson JL, Liu A, Do A, Liang J, Lin JJ.   +7 more
europepmc   +1 more source

Neoadjuvant Alectinib in a Patient With Anaplastic Lymphoma Kinase (ALK)-Mutant Stage III Lung Adenocarcinoma: A Case Report. [PDF]

Cureus
Dastagir ML, Bajaman J, Reynolds JA.
europepmc   +1 more source

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for therapeutic developments against cancer and chronic pain. [PDF]

Front Bioinform
Alrouji M, Alshammari MS, Alhajlah S, Tasqeeruddin S, Dinislam K, Shamsi A, Anwar S.   +6 more
europepmc   +1 more source

Pathological Complete Response in Locally Advanced <i>ALK</i> Fusion Gene-Positive Lung Adenocarcinoma following Salvage Surgery: A Case Report and Literature Review. [PDF]

Surg Case Rep
Ohta K, Haratake N, Takamori S, Abe Y, Kudo E, Sato T, Kamada K, Noda D, Abe M, Takumi Y, Miyawaki M, Daa T, Sugio K, Osoegawa A.   +13 more
europepmc   +1 more source